233 related articles for article (PubMed ID: 35868257)
21. Surgery for Glioblastoma: Impact of the Combined Use of 5-Aminolevulinic Acid and Intraoperative MRI on Extent of Resection and Survival.
Coburger J; Hagel V; Wirtz CR; König R
PLoS One; 2015; 10(6):e0131872. PubMed ID: 26115409
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
23. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
[TBL] [Abstract][Full Text] [Related]
24. Prognostic evaluation of patients with glioblastoma using a new score prediction model.
She L; Mao X; Su L; Liu Z
Eur J Surg Oncol; 2023 Sep; 49(9):106902. PubMed ID: 37076410
[TBL] [Abstract][Full Text] [Related]
25. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
Wick A; Kessler T; Platten M; Meisner C; Bamberg M; Herrlinger U; Felsberg J; Weyerbrock A; Papsdorf K; Steinbach JP; Sabel M; Vesper J; Debus J; Meixensberger J; Ketter R; Hertler C; Mayer-Steinacker R; Weisang S; Bölting H; Reuss D; Reifenberger G; Sahm F; von Deimling A; Weller M; Wick W
Neuro Oncol; 2020 Aug; 22(8):1162-1172. PubMed ID: 32064499
[TBL] [Abstract][Full Text] [Related]
26. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.
Kreth FW; Thon N; Simon M; Westphal M; Schackert G; Nikkhah G; Hentschel B; Reifenberger G; Pietsch T; Weller M; Tonn JC;
Ann Oncol; 2013 Dec; 24(12):3117-23. PubMed ID: 24130262
[TBL] [Abstract][Full Text] [Related]
27. Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis.
Lu VM; Goyal A; Graffeo CS; Perry A; Burns TC; Parney IF; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Jul; 127():31-37. PubMed ID: 30947000
[TBL] [Abstract][Full Text] [Related]
28. MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold.
Katsigiannis S; Grau S; Krischek B; Er K; Pintea B; Goldbrunner R; Stavrinou P
Neurosurgery; 2021 Mar; 88(4):E323-E329. PubMed ID: 33432978
[TBL] [Abstract][Full Text] [Related]
29. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
30. Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients.
Ene CI; Cimino PJ; Fine HA; Holland EC
Neurosurg Focus; 2020 Oct; 49(4):E11. PubMed ID: 33002863
[TBL] [Abstract][Full Text] [Related]
31. Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients.
Friso F; Rucci P; Rosetti V; Carretta A; Bortolotti C; Ramponi V; Martinoni M; Palandri G; Zoli M; Badaloni F; Franceschi E; Asioli S; Fabbri VP; Rustici A; Foschini MP; Brandes AA; Mazzatenta D; Sturiale C; Conti A
Neurosurgery; 2021 Nov; 89(6):1042-1051. PubMed ID: 34662898
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
33. Effect of Extent of Resection on Survival of Patients with Glioblastoma, IDH-Wild-Type, WHO Grade 4 (WHO 2021): Systematic Review and Meta-Analysis.
Jusue-Torres I; Lee J; Germanwala AV; Burns TC; Parney IF
World Neurosurg; 2023 Mar; 171():e524-e532. PubMed ID: 36529434
[TBL] [Abstract][Full Text] [Related]
34. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
35. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
[TBL] [Abstract][Full Text] [Related]
36. Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery.
Shah AS; Sylvester PT; Yahanda AT; Vellimana AK; Dunn GP; Evans J; Rich KM; Dowling JL; Leuthardt EC; Dacey RG; Kim AH; Grubb RL; Zipfel GJ; Oswood M; Jensen RL; Sutherland GR; Cahill DP; Abram SR; Honeycutt J; Shah M; Tao Y; Chicoine MR
J Neurosurg; 2020 Oct; 135(2):505-514. PubMed ID: 33035996
[TBL] [Abstract][Full Text] [Related]
37. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.
Pessina F; Navarria P; Cozzi L; Ascolese AM; Simonelli M; Santoro A; Clerici E; Rossi M; Scorsetti M; Bello L
J Neurooncol; 2017 Oct; 135(1):129-139. PubMed ID: 28689368
[TBL] [Abstract][Full Text] [Related]
38. Impact of Intraoperative Magnetic Resonance Imaging and Other Factors on Surgical Outcomes for Newly Diagnosed Grade II Astrocytomas and Oligodendrogliomas: A Multicenter Study.
Yahanda AT; Patel B; Shah AS; Cahill DP; Sutherland G; Honeycutt J; Jensen RL; Rich KM; Dowling JL; Limbrick DD; Dacey RG; Kim AH; Leuthardt EC; Dunn GP; Zipfel GJ; Leonard JR; Smyth MD; Shah MV; Abram SR; Evans J; Chicoine MR
Neurosurgery; 2020 Dec; 88(1):63-73. PubMed ID: 32717067
[TBL] [Abstract][Full Text] [Related]
39. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
40. Impact of extent of resection and recurrent surgery on clinical outcome and overall survival in a consecutive series of 170 patients for glioblastoma in intraoperative high field magnetic resonance imaging.
Coburger J; Wirtz CR; König RW
J Neurosurg Sci; 2017 Jun; 61(3):233-244. PubMed ID: 26149222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
